YD Bio Ltd

Das jüngste Quartal, das uns für YD Bio Ltd vorliegt

Aus dem eigenen 6-K des Unternehmens.

Was das Management sagte

“2025 was a highly transformative and foundational year for YD Bio, characterized by the successful capitalization of our long-term strategic vision. The successful completion of our business combination with Breeze Holdings Acquisition Corp. in August 2025, alongside a $13.2 million private investment in public equity (PIPE) financing, helped to significantly strengthen our balance sheet. Furthermore, we achieved a 17% increase in net revenue, driven predominantly by expanded pharmaceutical sales volumes and strategic new product launches,”

Wörtlich aus der Veröffentlichung zitiert und nur gezeigt, wenn die Einreichung es einer namentlich genannten Person zuordnet.

Was YD Bio Ltd macht

YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. The Company operates DNA methylation–based oncology testing programs in the United States under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. In addition, the Company maintains regulated ocular health commercialization operations and a consumer health distribution platform in Asia. Through strategic partnerships and scalable execution capabilities, the Company aims to advance biomedical innovation with real-world clinical and commercial impact.

Die Selbstbeschreibung des Unternehmens, wie sie am Fuß der Veröffentlichung steht.